As well as supporting GP practices to identify patients most likely to have FH, the tool has the following added benefits:
provides a prevalence rate for FH within the practice population compared with the expected rate;
identifies patients who would be above the higher risk threshold if their family history of CHD was positive and in whom it would be advisable to take or check family history of CHD;
facilitates the use of other FH case finding approaches, including the NICE screening threshold, Simon-Broome, and Dutch Lipid Clinical Network (DLCN);
identifies patients with an existing diagnosis of FH who do not have evidence of meeting the NICE highest risk criteria and in whom it would be advisable to check the FH diagnosis;
identifies patients with an existing diagnosis of FH where there are opportunities to review their lipid lowering treatment.
How would you rate your experience today?
Please rate your experience
What were you looking for today?
Please select what you were looking for today
How can we contact you?
Please enter a valid email address
What could we do better?
Please enter the verfication code
Thank you for providing us with your feedback.